Isogenica

Isogenica Limited is a biotechnology company based in Little Chesterford, United Kingdom, specializing in the design and licensing of synthetic antibody libraries and display technologies aimed at facilitating antibody discovery. Founded in 1998, the company offers several advanced systems, including the llamdA System, a single-domain antibody library; the Xab System, which features fully and semi-synthetic human antibody fragments; and the 4D Fab System, a synthetic human antibody library. Isogenica also provides peptide and scaffold platforms, leveraging its innovative vitro display technology known as CIS display to discover biologically active peptides, proteins, and antibodies. The company develops versatile small-format antibodies for constructing biotherapeutics targeting cancer, inflammation, and other serious diseases. These antibodies can be utilized in creating bispecific and multi-specific therapies or as components in targeted drug delivery systems, including antibody-drug conjugates and cell and gene therapies. Isogenica Limited primarily serves pharmaceutical and biotechnology companies, contributing significant advancements in the field of medical research.

William Eldridge Ph.D

CEO and Board Member

1 past transactions

Karyon-CTT

Acquisition in 2008
Karyon, Ltd. develops peptides into carriers for use in cancer diagnostics, imaging, and therapy. It offers Karyon Targeting Unit, a synthetic peptide that targets specific tumor tissue. The company engages in the areas of cancer biology and cell growth regulation, angiogenesis, biochemistry, peptide chemistry, organic syntheses and immunohistochemistry. Karyon, Ltd. was founded in 2001 and is based in Helsinki, Finland. As of May 6, 2008, Karyon Ltd. operates as a subsidiary of Isogenica Limited.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.